{
    "questions": [
        "Which antiplatelet drugs are recommended for ACS patients undergoing PCI?",
        "How long is dual antiplatelet therapy indicated for ACS patients not at high bleeding risk?",
        "What is the recommended lipid-lowering therapy for ACS patients on maximally tolerated statins?",
        "Which invasive strategy is recommended for non-ST-segment elevation ACS patients at intermediate or high ischemic risk?",
        "Which procedural approaches are recommended for ACS patients undergoing PCI to reduce complications?"
    ],
    "answers": [
        "Ticagrelor or prasugrel are recommended, preferred over clopidogrel for ACS patients undergoing PCI.",
        "At least 12 months, with strategies such as proton pump inhibitors, ticagrelor monotherapy after 1 month, or aspirin discontinuation in patients on long-term anticoagulation to reduce bleeding risk.",
        "High-intensity statin therapy is recommended for all ACS patients. For those already on maximally tolerated statins: add a non-statin agent (e.g., ezetimibe, evolocumab, alirocumab, or inclisiran) if LDL cholesterol is â‰¥70 mg/dL (1.8 mmol/L). Further intensification is reasonable in high-risk patients if LDL is 55 to <70 mg/dL (1.4 to <1.8 mmol/L).",
        "An invasive approach with intent to proceed with revascularization during hospitalization is recommended.",
        "Radial access is preferred over femoral to reduce bleeding and vascular complications, and intracoronary imaging is recommended to guide PCI in complex lesions."
    ]
}   